WO2011019686A1 - Cross-flow membrane filtration-based process for protein recovery - Google Patents
Cross-flow membrane filtration-based process for protein recovery Download PDFInfo
- Publication number
- WO2011019686A1 WO2011019686A1 PCT/US2010/044964 US2010044964W WO2011019686A1 WO 2011019686 A1 WO2011019686 A1 WO 2011019686A1 US 2010044964 W US2010044964 W US 2010044964W WO 2011019686 A1 WO2011019686 A1 WO 2011019686A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- interest
- membrane
- conditions
- cross
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 164
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 164
- 238000000034 method Methods 0.000 title claims abstract description 103
- 238000005374 membrane filtration Methods 0.000 title claims abstract description 43
- 238000011084 recovery Methods 0.000 title claims description 21
- 239000012528 membrane Substances 0.000 claims abstract description 132
- 230000000717 retained effect Effects 0.000 claims abstract description 35
- 230000014759 maintenance of location Effects 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 52
- 101710091977 Hydrophobin Proteins 0.000 claims description 38
- 239000012465 retentate Substances 0.000 claims description 36
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 238000000746 purification Methods 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 15
- 239000011148 porous material Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000002518 antifoaming agent Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 abstract 1
- 239000012466 permeate Substances 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 42
- 238000001471 micro-filtration Methods 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 27
- 238000000855 fermentation Methods 0.000 description 22
- 230000004151 fermentation Effects 0.000 description 22
- 239000007788 liquid Substances 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 14
- 238000009295 crossflow filtration Methods 0.000 description 14
- 239000006166 lysate Substances 0.000 description 14
- 238000001914 filtration Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 241000223259 Trichoderma Species 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000004695 Polyether sulfone Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 239000012538 diafiltration buffer Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 229920006393 polyether sulfone Polymers 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 241000228437 Cochliobolus Species 0.000 description 2
- 241000201144 Dufourea flammea Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001656512 Moniliophthora perniciosa Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241000222481 Schizophyllum commune Species 0.000 description 2
- 241000499912 Trichoderma reesei Species 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000008394 flocculating agent Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000222532 Agrocybe Species 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001502779 Aspergillus arvii Species 0.000 description 1
- 241001449939 Aspergillus aureolus Species 0.000 description 1
- 241001277109 Aspergillus brevipes Species 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 241001277112 Aspergillus duricaulis Species 0.000 description 1
- 241000131303 Aspergillus ellipticus Species 0.000 description 1
- 241000131363 Aspergillus fennelliae Species 0.000 description 1
- 241001507865 Aspergillus fischeri Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000824759 Aspergillus fumisynnematus Species 0.000 description 1
- 241001194141 Aspergillus hiratsukae Species 0.000 description 1
- 241001149711 Aspergillus lentulus Species 0.000 description 1
- 241000131350 Aspergillus neoglaber Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001232215 Aspergillus otanii Species 0.000 description 1
- 241000131370 Aspergillus quadricinctus Species 0.000 description 1
- 241000131371 Aspergillus spathulatus Species 0.000 description 1
- 241001507862 Aspergillus spinosus Species 0.000 description 1
- 241001277110 Aspergillus stramenius Species 0.000 description 1
- 241000131366 Aspergillus thermomutatus Species 0.000 description 1
- 241000306560 Aspergillus udagawae Species 0.000 description 1
- 241000131381 Aspergillus unilateralis Species 0.000 description 1
- 241001277111 Aspergillus viridinutans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 1
- 241001302652 Bassiana Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241001149956 Cladosporium herbarum Species 0.000 description 1
- 241000221760 Claviceps Species 0.000 description 1
- 241000124232 Claviceps fusiformis Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241001522757 Coccidioides posadasii Species 0.000 description 1
- 241001429695 Colletotrichum graminicola Species 0.000 description 1
- 241001480579 Crinipellis Species 0.000 description 1
- 241000221755 Cryphonectria Species 0.000 description 1
- 241000221756 Cryphonectria parasitica Species 0.000 description 1
- 241001532600 Dictyonema Species 0.000 description 1
- 241000366335 Dictyonema glabratum Species 0.000 description 1
- 241000648461 Dufourea <ascomycete lichen> Species 0.000 description 1
- 241000648714 Dufourea capensis Species 0.000 description 1
- 241000648721 Dufourea karrooensis Species 0.000 description 1
- 241000648705 Dufourea ligulata Species 0.000 description 1
- 241000648707 Dufourea turbinata Species 0.000 description 1
- 241000228138 Emericella Species 0.000 description 1
- 241001537207 Flammulina Species 0.000 description 1
- 240000006499 Flammulina velutipes Species 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- 241000233732 Fusarium verticillioides Species 0.000 description 1
- 241001620302 Glomerella <beetle> Species 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 241000735452 Heterobasidion Species 0.000 description 1
- 241000735439 Heterobasidion annosum Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241001149568 Laccaria Species 0.000 description 1
- 241000222435 Lentinula Species 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241001344133 Magnaporthe Species 0.000 description 1
- 241001330975 Magnaporthe oryzae Species 0.000 description 1
- 241001480581 Marasmius Species 0.000 description 1
- 241000278297 Marasmius cladophyllus Species 0.000 description 1
- 241000242611 Moniliophthora Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001507755 Neosartorya Species 0.000 description 1
- 241001232197 Neosartorya nishimurae Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 241001149548 Neurospora discreta Species 0.000 description 1
- 241000221962 Neurospora intermedia Species 0.000 description 1
- 244000070804 Neurospora sitophila Species 0.000 description 1
- 235000000376 Neurospora sitophila Nutrition 0.000 description 1
- 241000121264 Neurospora tetrasperma Species 0.000 description 1
- 241000221871 Ophiostoma Species 0.000 description 1
- 241000144580 Ophiostoma novo-ulmi Species 0.000 description 1
- 241001547409 Ophiostoma quercus Species 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241000899402 Passalora Species 0.000 description 1
- 241000222291 Passalora fulva Species 0.000 description 1
- 241000222543 Paxillus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 241001634117 Phlebiopsis Species 0.000 description 1
- 241001634106 Phlebiopsis gigantea Species 0.000 description 1
- 239000005817 Phlebiopsis gigantea (several strains) Substances 0.000 description 1
- 241001503957 Pisolithus Species 0.000 description 1
- 241001503962 Pisolithus tinctorius Species 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- 241000221945 Podospora Species 0.000 description 1
- 241000221946 Podospora anserina Species 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 241001492489 Postia placenta Species 0.000 description 1
- 241000228453 Pyrenophora Species 0.000 description 1
- 241000190117 Pyrenophora tritici-repentis Species 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000228341 Talaromyces Species 0.000 description 1
- 241001523006 Talaromyces marneffei Species 0.000 description 1
- 241001136489 Talaromyces stipitatus Species 0.000 description 1
- 241001460073 Trichoderma asperellum Species 0.000 description 1
- 241000894120 Trichoderma atroviride Species 0.000 description 1
- 241000303715 Trichoderma lixii Species 0.000 description 1
- 241001149558 Trichoderma virens Species 0.000 description 1
- 241000223261 Trichoderma viride Species 0.000 description 1
- 241000121219 Tricholoma Species 0.000 description 1
- 241001290329 Tricholoma terreum Species 0.000 description 1
- 241001465200 Uncinocarpus Species 0.000 description 1
- 241001465202 Uncinocarpus reesii Species 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 241001123668 Verticillium dahliae Species 0.000 description 1
- 241000018658 Xanthoria Species 0.000 description 1
- 241000216786 Xanthoria calcicola Species 0.000 description 1
- 241001542634 Xanthoria ectaneoides Species 0.000 description 1
- 241001542640 Xanthoria parietina Species 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- -1 complexes Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011968 cross flow microfiltration Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/149—Multistep processes comprising different kinds of membrane processes selected from ultrafiltration or microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/22—Controlling or regulating
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/16—Flow or flux control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/18—Details relating to membrane separation process operations and control pH control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2642—Aggregation, sedimentation, flocculation, precipitation or coagulation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/14—Batch-systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2317/00—Membrane module arrangements within a plant or an apparatus
- B01D2317/02—Elements in series
- B01D2317/022—Reject series
Definitions
- the present methods relate to the purification and concentration of proteins using membrane filtration, and to proteins produced by such methods.
- this clarified liquid containing the protein of interest may meet the requirements for formulation to produce the product. Other times, further processing is required to increase the concentration and/or purity of the protein prior to formulation. Concentration involves dewatering, which, for heat sensitive proteins, is typically achieved by ultrafiltration.
- the method further comprising: exposing the protein of interest retained by the first cross-flow membrane to a second cross-flow membrane, under a second set of conditions that cause the protein of interest pass through the second membrane as filtrate to allow purification and/or recovery of the protein of interest.
- the first membrane has a pore size of from about 0.02 ⁇ m to about 10 ⁇ m. In some embodiments, the first membrane and the second membrane independently have a pore size of from about 0.02 ⁇ m to about 10 ⁇ m. In some embodiments, the first membrane and the second membrane have substantially the same pore size. In some embodiments, the first membrane and the second membrane are the same membrane. In some embodiments, the first membrane is a series of membranes. In some embodiments, the first and/or second membrane is/are a series of membranes. In some embodiments, a single cross-flow membrane apparatus contains all the membranes used in the method. In some embodiments, the first and second membranes are in separate cross-flow membrane apparatus.
- the first set of conditions cause the protein of interest to exhibit an apparent molecular weight greater than its true molecular weight.
- the second set of conditions cause the protein of interest to exhibit its true molecular weight.
- the first set of conditions cause the protein of interest to form multimers, to aggregate, to crystallize, to precipitate, to form a gel, or combinations, thereof.
- the first set of conditions differs from the second set of conditions in transmembrane pressure, cross-flow, and/or solids concentration.
- the first set of conditions uses a transmembrane pressure that causes retention of the protein of interest on the first membrane and where the second set of conditions uses a transmembrane pressure that allows permeation of the protein of interest through the second membrane.
- the first set of conditions differs from the second set of conditions in salt concentration, surfactant concentration, polymer concentration, chaotrope concentration, reducing agent concentration, anti-foam concentration, precipitant concentration, pH, or temperature.
- the protein of interest is an enzyme. In some embodiments, the protein of interest is hydrophobin.
- the cross-flow filtration membrane of step (a) is different from that employed in step (b). In some embodiments, step (a) and step (b) use the same type of cross-flow filtration membrane.
- both steps are operated in one and the same cross-flow filtration unit apparatus. In some embodiments, each step is operated in a separate cross-flow membrane unit apparatus.
- a protein of interest produced by any of the embodiments of the method is provided.
- the protein is an enzyme, a structural protein, or a surface active protein.
- the protein is an amylase or hydrophobin.
- Figure 2 is an image of a SDS-PAGE gel showing the protein profiles obtained using a conventional microfiltration process.
- Molecular weight marker (lane M), diluted broth (lane 1 ), retentate (lane 2), permeate (lane 3).
- the arrow indicates hydrophobin.
- Figure 4 shows a series of reverse-phase (RP) HPLC traces showing the purification of hydrophobin during an exemplary microfiltration process.
- Figure 5 is a graph tracking the passage of an alpha-amylase from
- Figure 6 shows an image of a SDS-PAGE gel showing the protein profiles of various samples obtained during an exemplary microfiltration process.
- Hydrophobin standard (lane 1 ), molecular weight marker (lane 2), sodium sulfate treated concentrate (lane 3), sodium sulfate diafiltered concentrate (lane 4), cumulative sodium sulfate permeate (lane 5), sodium sulfate permeate at the start of the process (lane 6), sodium sulfate permeate at 83 kg cumulative permeate (lane 7), sodium sulfate permeate at 166 kg cumulative permeate (lane 8), sodium sulfate permeate at 250 kg cumulative permeate (lane 9).
- Figure 7 is a graph showing the retention of hydrophobin over the course of an exemplary microfiltration process. The hydrophobin concentration in the retentate remains constant during diafiltration with sodium acetate buffer.
- Figure 8 is a graph showing the activity-to-dry solids ratio of hydrophobin over the course of an exemplary microfiltration process. The enzyme purity increases over time as inactive dry solids are removed with the diafiltration buffer.
- Figure 9 is an image showing the physical appearance of the products lysate (tube 1 ), treated lysate (lane 2), sodium acetate buffer permeate (lane 3), diafiltered lysate in sorbitol/water/calcium chloride (lane 4), and sorbitol/calcium chloride permeate (lane 5), from an exemplary microfiltration process.
- Figure 10 is a graph showing the activity-to-dry solids ratio of hydrophobin over the course of an exemplary microfiltration process. The enzyme purity increases over time as inactive dry solids are removed with the diafiltration buffer.
- the methods involve applying a culture solution comprising a protein of interest to a cross-flow membrane filtration membrane under a first set of conditions that cause the protein of interest to be retained by the cross-flow membrane filtration membrane; and then exposing the culture solution retained by the first cross-flow membrane filtration membrane to a second cross-flow membrane filtration under a set of conditions that cause the protein of interest to pass through the second cross-flow membrane filtration membrane into the filtrate.
- the protein of interest is first retained by the cross-flow membrane filtration membrane to allow purification and/or concentration and/or buffer exchange, and then passed through a cross-flow membrane filtration membrane to allow purification and/or recovery.
- the culture solution comprising the protein of interest is a cell broth that includes intact cells and/or cell debris
- the present methods allow cell separation and protein
- the concentration to be performed using a single cross-flow filtration membrane can be used directly to formulate an end product.
- Microfiltration is conventionally used to retain cell debris and pass proteins, e.g., for cell separation, while ultrafiltration is conventionally used to retain proteins and pass solutes, e.g., for concentration.
- the present methods uses cross-flow membranes filtration to retain proteins that would otherwise pass into the permeate, an in some embodiments further use cross-flow membranes filtration for cell separation.
- the present methods are specifically applicable to culture solutions with soluble protein of interest, rather than insoluble protein or inclusion bodies, which would be expected to be retained by a cross-flow filtration membrane.
- the present methods can be practiced using aqueous liquids, with no requirement for extraction of retained materials using organic solvents or chaotropic chemicals.
- the present methods are particularly useful where the apparent molecular weight of a protein of interest can be manipulated, e.g., by changing the salt
- a "protein of interest” is a macromolecule comprising 20 or more contiguous amino acid residues linked by peptide bonds, such as a polypeptide (also referred to as a protein), e.g., an enzyme, a structural protein, a binding protein, and/or a surface-active protein).
- a protein of interest can be a single protein or a mixture of two or more proteins of interest.
- a "culture solution” is a liquid comprising the protein of interest and other soluble or insoluble components from which the protein of interest is intended to be recovered.
- Such components include other proteins, non-proteinaceous impurities such as cells or cell debris, nucleic acids, polysaccharides, lipids, chemicals such as antifoam, flocculants, salts, sugars, vitamins, growth factors, precipitants, and the like.
- a “culture solution” may also be referred to as "protein solution,” “liquid media,” “diafiltered broth,” “clarified broth,” “concentrate,” “conditioned medium,” “fermentation broth,” “lysed broth,” “lysate,” “cell broth,” or simply “broth.”
- the cells if present, may be bacterial, fungal, plant, animal, human, insect, etc.
- a protein of interest is in a form in which "the apparent molecular weight is greater than the actual molecular weight” if it is in the form of a multimer (e.g., a dimer, trimer, tetramer, or oligomer), a micelle, a precipitate, an aggregate, a gel, a crystal, a fibril, a plaque, a conjugate, or combinations, thereof.
- a multimer e.g., a dimer, trimer, tetramer, or oligomer
- cross-flow membrane filtration refers to a separation technique for liquids that comprises contacting a culture solution containing several soluble or insoluble components with a filtration membrane in an apparatus in a manner that allows the culture solution to flow parallel to the membrane surface and allows at least some of the liquid to penetrate the filtration membrane, thereby separating components in the culture solution into retentate and filtrate.
- This can also be referred to, in various embodiments, as “membrane separation,” “membrane filtration,” “tangential flow membrane filtration,” “tangential flow filtration,” “cross-flow filtration,” “microfiltration,” or “ultrafiltration.”
- a "filtration membrane,” sometimes referred to simply as, a “membrane,” is a material that is permeable to liquids and, semipermeable for components dispersed in that liquid, depending on their size, charge, hydrophobicity, or other biophysical properties. The size of particles that can pass through a filtration membrane is determined by its pore size.
- filtrate and “permeate” refer to the material that passes through a membrane. They are used interchangeably.
- retentate refers to the material retained by a membrane.
- ultrafiltration refers to the filtration of liquid through a membrane having a pore size of about 0.001 ⁇ m to about 0.02 ⁇ m.
- diafiltration refers to a membrane based filtration that is used to reduce or remove those components in the retentate that can permeate through the membrane by adding more liquid to the retentate and filtering that additional volume of liquid through the membrane. Diafiltration is sometimes referred to as "buffer exchange”.
- passage refers to the movement of a fraction of a component from the retentate through the filtration membrane into the permeate.
- retention refers to the inability of a component to pass from the retentate through the filtration membrane into the permeate.
- uniform transmembrane pressure refers to a cross-flow filtration mode of operation where the pressure difference between the retentate side and the permeate side at the retentate inlet of the cross-flow filter is the same as the pressure difference between the retentate side and the permeate side at the retentate outlet of the cross-flow filter.
- Uniform transmembrane pressure can achieved, for example, by applying pressure to the permeate at the inlet of the cross-flow filter and restricting the permeate flow at the permeate outlet of the cross-flow filter.
- the phrase "pressure drop along the membrane element” refers to the pressure difference between the retentate inlet side of a cross-flow membrane filter element and the retentate outlet side of that membrane filter element.
- several cross-flow membrane elements are arranged in series in one membrane housing such that the retentate liquid from one element enters the inlet side of the next element in the series.
- the pressure drop across the entire series of membrane elements equals the "pressure drop along the membrane element" times the number of elements in the housing.
- a "protein product” refers to a protein preparation suitable for providing to an end user, such as a customer. Protein products may include buffers, salts, preservative, reducing agents, sugars, polyols, surfactants, and the like to prolong the shelf-life of the protein of interest.
- the present methods relate to the recovery of proteins using cross-flow membrane filtration, and to proteins produced by such methods.
- the method allows the purification and recovery of such proteins directly from fermentation broth using only a single membrane cross-flow membrane filtration apparatus.
- a feature of the present methods is the use of two sets of liquid conditions that differentially affect the retention behavior of the protein of interest.
- the protein of interest Under the first set of conditions, the protein of interest has an apparent molecular weight that is greater than their actual molecular weight, causing them to be retained by the cross-flow membrane filtration membrane.
- Examples of protein forms in which the apparent molecular weight that is greater than their actual molecular weight include, but are not limited to, multimers, aggregates, or other supramolecular structures, crystals, precipitates, gels, or combinations, thereof.
- the proteins of interest have an apparent molecular weight that allows them to pass through the cross-flow membrane filtration membrane. In this case, the apparent molecular weight may be the actual molecular weight.
- Conditions for causing the apparent molecular weight of a particular protein of interest to exceed its actual molecular weight can be determined using conventional methods for sizing macromolecules, including size exclusion chromatography, analytical ultracentrifugation, cross-flow membrane filtration.
- Exemplary solution conditions that can be manipulated to cause the apparent molecular weight of a protein of interest to exceed its actual molecular weight are the salt concentration, surfactant concentration, polymer concentration, reducing agent concentration, precipitant concentration, pH, or temperature. Such conditions may induce the formation of multimers, aggregates or supramolecular structures, crystals, precipitates, gels, complexes, conjugates, and the like.
- the particular form of the protein of interest that allows it to be retained by a cross-flow membrane filtration membrane is not critical, except to the extent that the protein of interest in that form, preferably with the native structure and function, must be retained by the membrane.
- membrane filtration is performed to retain, concentrate, or enrich the protein of interest, which cannot pass through the membrane. So long as the conditions maintain the protein of interest in a form where the apparent molecular weight of the protein prevents passage through the membrane, the protein solution can be modified as in the case of desalting, buffer exchange, removing unwanted components, addition of formulation components, and the like.
- Retention of the protein of interest can also be increased by the manner in which the cross-flow membrane filtration membrane process is operated. Proteins are retained by cross-flow membrane filtration membranes under conditions of high transmembrane pressure, low cross-flow and/or high retentate solids content. This mode of retention may be combined with the increased retention due to the change in apparent molecular weight of the protein of interest discussed in the previous sections.
- the method then involves altering the conditions of the culture solution to reduce the apparent molecular weight of the protein of interest. In some cases, the conditions cause the protein of interest to behave according to the true molecular weight.
- the method then involves recovering the protein of interest as filtrate (i.e., permeate or flow-through) from the membrane. In this manner, cells, cell debris, and other insoluble material are retained by the membrane. Other soluble components that have apparent size larger than the cross- flow membrane filtration membrane pore size are retained. The protein of interest previously retained by the membrane now passes through the cross-flow membrane filtration membrane.
- the passage of the protein of interest into the permeate in the second step of the method can also be accomplished, for example, by changing the operating conditions of the microfilter to those that facilitate the passage of protein of interest, e.g., low transmembrane pressure, high cross-flow and/or low retentate solids content.
- Other means of facilitating the passage of the protein of interest known in the art such as vibration, sonication, backpulsing, or air bubbles, can also be used.
- Such physical methods for controlling the passage of the protein of interest through the membrane may be combined with each other, as well as with the aforementioned modification of solution conditions to control the apparent molecular weight of the protein of interest.
- the method allows a single cross-flow membrane filtration membrane to be used to separate the protein of interest from cells and cell debris, concentrate the protein of interest, and recover the protein of interest in a preselected solution.
- Proteins of interest recovered by this method may be sufficiently free of other polypeptides and cellular materials and in a sufficient amount and concentration for formulation into a protein product. However, they can be subjected to further purification and/or concentration if desired.
- the methods have particular application in an industrial setting where over-expressed proteins can be recovered from broth in very few steps, in some cases in sufficient purity and concentration to use directly as a product.
- the methods can be applied to any enzyme or other protein capable of being induced to have an apparent molecular weight greater than its actual molecular weight by manipulation the solution conditions.
- Exemplary proteins are enzymes, as exemplified by Bacillus licheniformis ⁇ -amylase.
- the method can be applied to other enzymes and structural protein.
- hydrophobins a class of cysteine- rich polypeptides expressed by filamentous fungi.
- Hydrophobins are small ( ⁇ 100 amino acids) polypeptides known for their ability to form a hydrophobic coating on the surface of objects, including cells and man-made materials.
- hydrophobins are categorized as being class I or class II.
- hydrophobin conventionally requires the addition of a large amount of one or more antifoaming agents (i.e., antifoam) during fermentation.
- antifoaming agents i.e., antifoam
- hydrophobin polypeptides saturates breather filters, contaminates vents, causes pressure build-up, and reduces protein yield.
- crude concentrates of hydrophobin conventionally contain residual amounts of antifoam, as well as host cell contaminants, which are undesirable in a hydrophobin preparation, particularly when the hydrophobin is intended as a food additive.
- Hydrophobin can reversibly exist in forms having an apparent molecular weight that is greater than its actual molecular weight, which make hydrophobin well suited for recovery using the present methods.
- Liquid media containing hydrophobin may be combined with the foam or handled separately.
- Liquid or foam containing hydrophobin can be continuously or periodically harvested from a fermentor for protein recovery as described, or harvested in batch at the end of a fermentation operation.
- Liquid media containing hydrophobin may be combined with the foam or handled separately.
- the hydrophobin can be any class I or class Il hydrophobin known in the art, for example, hydrophobin from an Agahcus spp. (e.g., Agahcus bisporus), an Agrocybe spp. (e.g., Agrocybe aegerita), an Ajellomyces spp., (e.g., Ajellomyces capsulatus, Ajellomyces dermatitidis), an Aspergillus spp.
- an Agahcus spp. e.g., Agahcus bisporus
- an Agrocybe spp. e.g., Agrocybe aegerita
- an Ajellomyces spp. e.g., Ajellomyces capsulatus, Ajellomyces dermatitidis
- Aspergillus spp e.g., Ajellomyces capsulatus, Ajellomyces dermatitidis
- Aspergillus arvii Aspergillus brevipes, Aspergillus clavatus, Aspergillus duricaulis, Aspergillus ellipticus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus fumisynnematus, Aspergillus lentulus, Aspergillus niger, Aspergillus unilateralis, Aspergillus viridinutans
- a Beauveha spp. e.g., Beauveha bassiana
- a Coccidioides spp. e.g., Coccidioides posadasii
- a Cochliobolus spp. e.g., Cochliobolus
- Crinipellis spp. ⁇ e.g., Crinipellis perniciosa
- Cryphonectria spp. e.g., Cryphonectria parasitica
- Davidiella spp. e.g., Davidiella tassiana
- a Crinipellis spp. ⁇ e.g., Crinipellis perniciosa
- Cryphonectria spp. e.g., Cryphonectria parasitica
- Davidiella spp. e.g., Davidiella tassiana
- Dictyonema spp. e.g., Dictyonema glabratum
- an Emericella spp. e.g., Emericella nidulans
- a Flammulina spp. e.g., Flammulina velutipes
- Fusarium spp. ⁇ e.g., Fusahum culmorum a Gibberella spp. (e.g., Gibberella moniliformis), a Glomerella spp. (e.g., Glomerella graminicola), a Grifola spp. (e.g., Grifola frondosa), a
- Heterobasidion spp. e.g., Heterobasidion annosum
- a Hypocrea spp. e.g., Hypocrea jecorina, Hypocrea lixii, Hypocrea virens
- a Laccaria spp. e.g., Laccaha bicolor
- a Lentinula spp. e.g., Lentinula edodes
- a Magnaporthe spp. e.g., Magnaporthe oryzae
- a Marasmius spp. e.g., Marasmius cladophyllus
- Neosartorya spp. e.g., Neosartorya aureola, Neosartorya fennelliae, Neosartorya fischeri, Neosartorya glabra, Neosartorya hiratsukae,
- a Paracoccidioides spp. e.g., Paracoccidioides brasiliensis
- a Passalora spp. e.g., Passalora fulva
- Paxillus filamentosusPaxillus involutus e.g., Penicillium camemberti, Penicillium chrysogenum, Penicillium marneffei
- a Phlebiopsis gigantea e.g., Phlebiopsis gigantea
- a Pisolithus ⁇ e.g., Pisolithus tinctorius e.g., Pleurotus spp.
- Pleurotus spp. Pleurotus ostreatus
- a Podospora spp. e.g., Podospora anserina
- Posfra spp. e.g., Postia placenta
- a Pyrenophora spp. e.g., Pyrenophora tritici-repentis
- a Schizophyllum spp. e.g., Schizophyllum commune
- a Talaromyces spp. e.g.,
- Trichoderma spp. e.g., Trichoderma asperellum
- Tricholoma spp. e.g., Tricholoma terreum
- Uncinocarpus spp. e.g., Uncinocarpus reesii
- Verticillium spp. e.g., Verticillium dahliae
- Xanthodactylon spp. e.g.
- Culture solutions broadly include solutions comprising the protein of interest and other soluble or insoluble components from which the protein of interest is intended to be separated and recovered.
- Culture solutions include e.g., fermentation broth, cell suspensions, conditioned media, aqueous lysates, pre-filtered cell-free suspensions, cleared solutions, clarified solutions, concentrated culture solutions, concentrates, and the like.
- the culture solution may include intact or lysed cells, including bacterial, fungal, plant, animal, or insect cells.
- the culture solution may also include other proteins, non- proteinaceous impurities such as cells or cell debris, nucleic acids, polysaccharides, lipids, chemicals such as antifoam, flocculants, salts, sugars, vitamins, growth factors, precipitants, and the like.
- the cross-flow filtration membrane suitable for the present method should have pore size or molecular weight cut-off that is greater than the actual size of the protein of interest.
- Exemplary pore size of the cross-flow filtration membrane is from about 0.02 ⁇ m to about 10 ⁇ m, e.g., about 0.02 ⁇ m, 0.03 ⁇ m, 0.04 ⁇ m, 0.05 ⁇ m, 0.06 ⁇ m, 0.07 ⁇ m, 0.08 ⁇ m, 0.09 ⁇ m, 0.1 ⁇ m, 0.2 ⁇ m, 0.22 ⁇ m, 0.3 ⁇ m, 0.4 ⁇ m, 0.45 ⁇ m, 0.5 ⁇ m, 0.6 ⁇ m, 0.7 ⁇ m, 0.8 ⁇ m, 0.9 ⁇ m, 1 ⁇ m, 2 ⁇ m, 3 ⁇ m, 4 ⁇ m, 5 ⁇ m, 6 ⁇ m, 7 ⁇ m, 8 ⁇ m, 9 ⁇ m, 10 ⁇ m, and the like.
- Exemplary molecular weight cutoff is from about 1 kD to about 500 kD, e.g., about 1 kD, 5 kD, 10 kD, 20 kD, 50 kD, 100 kD, 200 kD, 500 kD.
- Exemplary types of cross-flow filtration membrane elements are spiral wound modules, tubular membranes, hollow fiber membranes, flatsheet membranes, and the like
- This Example illustrates a process for recovering a protein from fermentation broth using membrane filtration. 160 kg fermentation broth was prepared by culturing Trichoderma reseei that expressed recombinant hydrophobin using conventional techniques.
- the harvest broth was treated by addition of 40 kg of 10% sodium sulfate and the pH was adjusted to 3.9 with sulfuric acid. The mixture was warmed to 50 5 C and held for two hours. This operation produced 200 kg treated harvest broth.
- the treated harvest broth was fed to the retentate tank of a cross-flow microfiltration apparatus fitted with a 3.8" x 38" spiral wound KOCH MFK-618, 0.2 ⁇ m PES membrane.
- the retentate mass was first reduced to 120 kg by permeating 80 kg of filtrate, and then diafiltered at constant retentate volume with 270 kg of 2.5 % (w/w) sodium sulfate solution at 50 °C, 0.3 bar uniform trans-membrane pressure, and at 1 bar pressure drop along the membrane element. Based on SDS-PAGE analysis, the vast majority of hydrophobin was retained with the cells.
- the membrane permeate was directed back to the retentate tank while the diafiltered broth pH of the recirculating broth was raised to 6.2 by addition of 10% (w/w) sodium hydroxide solution to the retentate tank and the system was operated for 1 .4 hours in this mode.
- the broth at pH 6.2 was diafiltered with 320 kg of water, and then concentrated to 80 kg.
- the permeate product was collected and estimated to contain 91 % of the hydrophobin supplied in the initial fermentation broth.
- the average permeate flux for the entire process was about 25 kilograms per m 2 per hour.
- the SDS-PAGE gel in Figure 1 shows the protein profile of the initial broth (lane 1 ), the permeate product (lane 2), and the permeate waste (lane 3). Hydrophobin is predominantly found in the in the permeate product.
- Example 2 Conventional microfiltration recovery of protein from fermentation broth (comparative example)
- Example 1 300 kg fermentation broth was prepared using the same method as described in Example 1. The broth was diluted to 1 ,200 kg with water, and the diluted broth was concentrated to 100 kg by microfiltration under the same conditions as in Example 1. As shown in Figure 2 the hydrophobin and most of the protein impurities were permeated into the filtrate during the concentration step (lane 3). This is in contrast to the method described in Example 1 , where the hydrophobin was selectively retained in the first part of the process and only the impurities permeated into the filtrate.
- Treated broth was diafiltered with 740 kg of 0.5 % (w/w) sodium sulfate solution on a microfilter fitted with four 3.8" x 38" spiral wound (KOCH MFK-618, 0.2 ⁇ m PES) membranes in series at 50 °C, 0.3 bar uniform trans-membrane pressure, and at 0.75 bar pressure drop along each membrane element. Hydrophobin was retained with the cells. The average permeate flux was 30 kilograms per m 2 per hour.
- the broth at pH 5.4 was then diafiltered with 740 kg of water.
- the permeate was collected and estimated to contained 98% of the hydrophobin present in the initial fermentation broth.
- the average permeate flux for the whole process was 30 kilograms per m 2 per hour.
- the process yield was 94%.
- the graph in Figure 3 tracks hydrophobin during the microfiltration process.
- the word "switch” indicates the point in the process where diafiltration medium was changed from sodium sulfate to water and the broth pH was raised to 5.4.
- Figure 4 shown a series of RP-HPLC traces showing hydrophobin in the initial broth (A), sodium sulfate permeate (B), and water permeate (C). Significant purification of hydrophobin was achieved in the process.
- Example 4 Enzyme retention by manipulating the fluid conditions in a tangential flow microfilter
- Bacillus licheniformis that expressed recombinant ⁇ -amylase enzyme was fermented using conventional techniques. Following fermentation, the broth was lysed using 0.01 % (w/w) lysozyme for 2 hrs, followed by heat treatment at 60 °C for 2hr.
- the lysed broth was cooled and stored at 10°C until use.
- Cold lysed broth was diluted with 1 part of process water, heated to 50 °C in a jacketed tank, and then held for 2 hours with mixing while maintaining pH 6.5 ⁇ 0.2 using 5% NaOH.
- the diluted cell lysate was fed into the retentate tank of a microfiltration skid with a 3.8" spiral wound KOCH MFK-618, 0.2 ⁇ m PES microfiltration element, operated at 50 °C, 0.8 bar uniform trans-membrane pressure, and 1 .3 bar pressure drop along the membrane element.
- the cell lysate was first concentrated in the microfiltration unit about 3-fold. Then a feed of diluted cell lysate was started to the retentate while at the same time concentrated retentate was removed such that a constant packed solids content of retentate was maintained. As shown in Figure 5, the enzyme passage continuously declined during the process.
- a control experiment was run at 0.5 bar uniform transmembrane pressure with the other conditions the same as described above.
- This Example illustrates a process for recovering a protein from clarified culture solution using microfiltration.
- Clarified culture solution was prepared from fermentation broth described in Example 1 by separating the cells by dead end filtration and dewatering using ultrafiltration. 12 kg of 20% sodium sulfate solution was mixed with 83 kg of this culture solution concentrate, the pH was adjusted to 4.0 with sulfuric acid and the mixture was heated to 50 Q C in a jacketed process tank.
- This Example illustrates a process that produces formulated, purified enzyme from a fermentation broth on a single microfiltration unit operation.
- the diafiltered lysate was mixed with 8.7 parts (w/w) of Dl water and 5.3 parts (w/w) of 70% (w/w) sorbitol and 0.0012 parts (w/w) calcium chloride adjusted to pH 6.5 with sodium hydroxide solution. The mixture was incubated for 12 hours at 50 Q C.
- the lysate/sorbitol/calcium chloride mixture was then concentrated on the same Sepa Cell unit under the same operating conditions, except for the inlet pressure, which was maintained at 0.4 bar.
- the clear sorbitol/calcium chloride permeate was collected and contained 70% of the amylase enzyme.
- the graph in Figure 7 shows that the activity of enzyme is retained throughout the microfiltration process.
- the graph in Figure 8 shows the activity-to-dry solids ratio during the first microfiltration process. Enzyme purity increases as inactive dry solids are removed with the diafiltration buffer.
- the image in Figure 9 shows the physical appearance of the lysate (tube 1 ), treated lysate (tube 2), sodium acetate buffer permeate (tube 3), diafiltered lysate in sorbitol/water/calcium chloride (tube 4), and sorbitol/calcium chloride permeate (tube 5).
- Example 7 Enzyme recovery and formulation from cell free enzyme concentrate
- This Example illustrates a process similar to that described in Example 6, but for recovering an enzyme from a clarified culture solution.
- 2 kg of cell free enzyme concentrate was adjusted to pH 5 with acetic acid and incubated with mixing at 50 Q C for 44 hours.
- the prepared concentrate was diafiltered with 50 mM sodium acetate pH 5 on the same apparatus and under the same operating conditions as for the cell- containing lysate in Example 6.
- the enzyme/sorbitol/calcium chloride mixture was microfiltered under the same conditions as the enzyme concentrate, except that the inlet pressure was lowered to 0.5 bar.
- the graph in Figure 10 shows the activity-to-dry solids ratio during the first microfiltration process.
- the enzyme purity increased as inactive dry solids were removed with the diafiltration buffer.
- the Table in Figure 1 1 shows enzyme passage during the course of the microfiltration process. Passage refers to the ratio of permeate activity and retentate activity. As the permeate volume increased, enzyme passage slowed.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present methods relate to the isolation and concentration of proteins using cross-flow membrane filtration, and to proteins produced by such methods. A feature of the method is that the protein of interest is retained by a cross-flow membrane under certain conditions that promote retention, while under other condition the protein passes through the membrane.
Description
CROSS-FLOW MEMBRANE FILTRATION-BASED PROCESS FOR PROTEIN
RECOVERY
PRIORITY
[001] The present application claims priority to U.S. Provisional Patent Application No. 61/232,728, filed August 10, 2009, which is herein incorporated by reference in its entirety.
TECHNICAL FIELD
[002] The present methods relate to the purification and concentration of proteins using membrane filtration, and to proteins produced by such methods.
BACKGROUND
[003] Conventional recovery and formulation methods relating to proteins produced by microbial fermentation involve several processing steps (e.g., Enzymes in Industry: Production and Applications (2007) Wolfgang Aehle, ed., 3rd edition, Wiley- VCH, p. 49; Bioseparations: Science and Engineering (2003) R. G. Harrison et al., Oxford University Press, p. 32). Any one of a number of solid-liquid separation methods can be employed to produce a clarified solution containing the protein of interest.
[004] Depending on the desired final product concentration and purity, this clarified liquid containing the protein of interest may meet the requirements for formulation to produce the product. Other times, further processing is required to increase the concentration and/or purity of the protein prior to formulation. Concentration involves dewatering, which, for heat sensitive proteins, is typically achieved by ultrafiltration.
SUMMARY
[005] Described are methods relating to the purification and concentration of proteins using cross-flow membrane filtration, and to proteins produced by such methods.
[006] In on aspect, a method for recovering a protein of interest from a culture solution using cross-flow membrane filtration is provided, comprising: subjecting a culture solution comprising a protein of interest to cross-flow membrane filtration using a first membrane under a first set of conditions that cause the protein of interest to be retained as retentate to allow purification, concentration, and/or buffer exchange of the
protein of interest; wherein under a second set of conditions, the first membrane allows the passage of the protein of interest.
[007] In some embodiments, the method further comprising: exposing the protein of interest retained by the first cross-flow membrane to a second cross-flow membrane, under a second set of conditions that cause the protein of interest pass through the second membrane as filtrate to allow purification and/or recovery of the protein of interest.
[008] In some embodiments, the first membrane has a pore size of from about 0.02 μm to about 10 μm. In some embodiments, the first membrane and the second membrane independently have a pore size of from about 0.02 μm to about 10 μm. In some embodiments, the first membrane and the second membrane have substantially the same pore size. In some embodiments, the first membrane and the second membrane are the same membrane. In some embodiments, the first membrane is a series of membranes. In some embodiments, the first and/or second membrane is/are a series of membranes. In some embodiments, a single cross-flow membrane apparatus contains all the membranes used in the method. In some embodiments, the first and second membranes are in separate cross-flow membrane apparatus.
[009] In some embodiments, the culture solution comprising the protein of interest further comprises intact cells or cell debris, and wherein the intact cells or cell debris are retained on the first membrane, along with the protein of interest, under the first set of conditions. In some embodiments, the culture solution comprising the protein of interest further comprises intact cells or cell debris, and wherein the intact cells or cell debris are retained with the protein of interest under the first set of conditions and separated from the protein of interest under the second set of conditions. In some embodiments, the intact cells or cell debris are from filamentous fungi or bacteria. In some embodiments, the culture solution comprising the protein of interest further comprises additional molecules that are not retained by the first membrane.
[0010] In some embodiments, the first set of conditions cause the protein of interest to exhibit an apparent molecular weight greater than its true molecular weight. In some embodiments, the second set of conditions cause the protein of interest to exhibit its true molecular weight. In some embodiments, the first set of conditions cause the protein of interest to form multimers, to aggregate, to crystallize, to precipitate, to form a gel, or combinations, thereof.
[0011] In some embodiments, the first set of conditions differs from the second set of conditions in transmembrane pressure, cross-flow, and/or solids concentration. In some embodiments, the first set of conditions uses a transmembrane pressure that causes retention of the protein of interest on the first membrane and where the second set of conditions uses a transmembrane pressure that allows permeation of the protein of interest through the second membrane.
[0012] In some embodiments, the second set of conditions are in the form of an aqueous solution suitable for formulating the protein of interest into an end product.
[0013] In some embodiments, the first set of conditions differs from the second set of conditions in salt concentration, surfactant concentration, polymer concentration, chaotrope concentration, reducing agent concentration, anti-foam concentration, precipitant concentration, pH, or temperature.
[0014] In some embodiments, the protein of interest is an enzyme. In some embodiments, the protein of interest is hydrophobin.
[0015] In another aspect, a method for recovering a protein of interest from a culture solution using a cross-flow membrane filtration membrane is provided, comprising: (a) applying the culture solution comprising the protein of interest to a cross-flow
membrane filtration membrane under a first set of conditions that cause the protein of interest to be retained by the cross-flow membrane filtration membrane; and (b) exposing the protein of interest retained by the cross-flow membrane filtration membrane to a second set of conditions that cause the protein of interest to pass through the cross-flow membrane filtration membrane as filtrate; wherein the protein of interest is first retained by the cross-flow membrane filtration membrane to allow purification and/or concentration and/or buffer exchange, and then passed through the cross-flow membrane filtration membrane to allow cell separation and/or purification and/or recovery.
[0016] In some embodiments, the cross-flow filtration membrane of step (a) is different from that employed in step (b). In some embodiments, step (a) and step (b) use the same type of cross-flow filtration membrane.
[0017] In some embodiments, both steps are operated in one and the same cross-flow filtration unit apparatus. In some embodiments, each step is operated in a separate cross-flow membrane unit apparatus.
[0018] Other embodiments of this aspect of the methods are described above and below.
[0019] In another aspect, a protein of interest produced by any of the embodiments of the method is provided. In some embodiments, the protein is an enzyme, a structural protein, or a surface active protein. In particular embodiments, the protein is an amylase or hydrophobin.
[0020] These and other aspects and embodiments of the compositions and methods will be apparent from the present description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 is an image of a SDS-PAGE gel showing the protein profiles at different stages of an exemplary microfiltration process. Initial broth (lane 1 ), permeate product (lane 2), and permeate waste (lane 3). The arrow indicates hydrophobin.
[0022] Figure 2 is an image of a SDS-PAGE gel showing the protein profiles obtained using a conventional microfiltration process. Molecular weight marker (lane M), diluted broth (lane 1 ), retentate (lane 2), permeate (lane 3). The arrow indicates hydrophobin.
[0023] Figure 3 is a graph tracking the localization of hydrophobin during an exemplary microfiltration process. The word "switch" indicates the point in the process where the diafiltration medium was changed from sodium sulfate to water and the pH of the broth was raised to 5.4.
[0024] Figure 4 shows a series of reverse-phase (RP) HPLC traces showing the purification of hydrophobin during an exemplary microfiltration process. Initial broth (A), sodium sulfate permeate (B), and water permeate (C).
[0025] Figure 5 is a graph tracking the passage of an alpha-amylase from
fermentation broth through a microfilter operated at 0.8 bar transmembrane pressure (triangles) and at 0.5 bar transmembrane pressure (squares).
[0026] Figure 6 shows an image of a SDS-PAGE gel showing the protein profiles of various samples obtained during an exemplary microfiltration process. Hydrophobin standard (lane 1 ), molecular weight marker (lane 2), sodium sulfate treated concentrate (lane 3), sodium sulfate diafiltered concentrate (lane 4), cumulative sodium sulfate permeate (lane 5), sodium sulfate permeate at the start of the process (lane 6), sodium sulfate permeate at 83 kg cumulative permeate (lane 7), sodium sulfate permeate at 166 kg cumulative permeate (lane 8), sodium sulfate permeate at 250 kg cumulative permeate (lane 9).
[0027] Figure 7 is a graph showing the retention of hydrophobin over the course of an exemplary microfiltration process. The hydrophobin concentration in the retentate remains constant during diafiltration with sodium acetate buffer.
[0028] Figure 8 is a graph showing the activity-to-dry solids ratio of hydrophobin over the course of an exemplary microfiltration process. The enzyme purity increases over time as inactive dry solids are removed with the diafiltration buffer.
[0029] Figure 9 is an image showing the physical appearance of the products lysate (tube 1 ), treated lysate (lane 2), sodium acetate buffer permeate (lane 3), diafiltered lysate in sorbitol/water/calcium chloride (lane 4), and sorbitol/calcium chloride permeate (lane 5), from an exemplary microfiltration process.
[0030] Figure 10 is a graph showing the activity-to-dry solids ratio of hydrophobin over the course of an exemplary microfiltration process. The enzyme purity increases over time as inactive dry solids are removed with the diafiltration buffer.
[0031] Figure 1 1 is a table showing enzyme passage during the course of the microfiltration process. Passage refers to the ratio of permeate activity and retentate activity. As the permeate volume increased, enzyme passage slowed.
DETAILED DESCRIPTION
A. Overview of the Method
[0032] Described are methods relating to the recovery of a protein of interest from a culture solution using cross-flow membrane filtration, in which the protein of interest is retained by a cross-flow filtration membrane of a type that would normally allow it to pass. This is accomplished by appropriate conditioning of the culture solution and/or the choice of cross-flow filtration operating conditions. This allows purification of the protein of interest, concentration, and/or buffer exchange.
[0033] Also described are methods relating to the purification and concentration of proteins using cross-flow membrane filtration, and to proteins produced by such methods. The methods involve applying a culture solution comprising a protein of interest to a cross-flow membrane filtration membrane under a first set of conditions that cause the protein of interest to be retained by the cross-flow membrane filtration membrane; and then exposing the culture solution retained by the first cross-flow membrane filtration membrane to a second cross-flow membrane filtration under a set of conditions that cause the protein of interest to pass through the second cross-flow membrane filtration membrane into the filtrate. Using this method, the protein of
interest is first retained by the cross-flow membrane filtration membrane to allow purification and/or concentration and/or buffer exchange, and then passed through a cross-flow membrane filtration membrane to allow purification and/or recovery. Where the culture solution comprising the protein of interest is a cell broth that includes intact cells and/or cell debris, the present methods allow cell separation and protein
concentration to be performed using a single cross-flow filtration membrane. In some cases the resulting protein filtrate can be used directly to formulate an end product.
[0034] Microfiltration is conventionally used to retain cell debris and pass proteins, e.g., for cell separation, while ultrafiltration is conventionally used to retain proteins and pass solutes, e.g., for concentration. The present methods uses cross-flow membranes filtration to retain proteins that would otherwise pass into the permeate, an in some embodiments further use cross-flow membranes filtration for cell separation. The present methods are specifically applicable to culture solutions with soluble protein of interest, rather than insoluble protein or inclusion bodies, which would be expected to be retained by a cross-flow filtration membrane. In addition, the present methods can be practiced using aqueous liquids, with no requirement for extraction of retained materials using organic solvents or chaotropic chemicals.
[0035] The present methods are particularly useful where the apparent molecular weight of a protein of interest can be manipulated, e.g., by changing the salt
concentration, surfactant concentration, polymer concentration, anti-foam
concentration, precipitant concentration, pH, temperature, or other parameters in a liquid medium. It is preferable that such manipulations do not irreversibly affect the structure and/or function of the protein of interest.
[0036] The present methods are particularly useful when the membrane retention behavior of the protein in solution can controlled by the choice of the operating conditions used in conjunction with the cross-flow membrane filtration membrane. For example, proteins can be caused to be retained on a membrane by using high transmembrane pressure, low cross-flow and high retentate solids content, or combination of these conditions. Conversely, proteins can be caused to pass into the permeate by operating at low transmembrane pressure, high cross-flow, low retentate solids concentration, with vibration, sonication, backpulsing, or air bubbling, or combinations of these conditions.
B. Definitions
[0037] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The following abbreviations and/or terms are defined for clarity.
[0038] As used herein, a "protein of interest" is a macromolecule comprising 20 or more contiguous amino acid residues linked by peptide bonds, such as a polypeptide (also referred to as a protein), e.g., an enzyme, a structural protein, a binding protein, and/or a surface-active protein). A protein of interest can be a single protein or a mixture of two or more proteins of interest.
[0039] As used herein, a "culture solution" is a liquid comprising the protein of interest and other soluble or insoluble components from which the protein of interest is intended to be recovered. Such components include other proteins, non-proteinaceous impurities such as cells or cell debris, nucleic acids, polysaccharides, lipids, chemicals such as antifoam, flocculants, salts, sugars, vitamins, growth factors, precipitants, and the like. A "culture solution" may also be referred to as "protein solution," "liquid media," "diafiltered broth," "clarified broth," "concentrate," "conditioned medium," "fermentation broth," "lysed broth," "lysate," "cell broth," or simply "broth." The cells, if present, may be bacterial, fungal, plant, animal, human, insect, etc.
[0040] As used herein, a protein of interest is in a form in which "the apparent molecular weight is greater than the actual molecular weight" if it is in the form of a multimer (e.g., a dimer, trimer, tetramer, or oligomer), a micelle, a precipitate, an aggregate, a gel, a crystal, a fibril, a plaque, a conjugate, or combinations, thereof.
[0041] As used herein, the term "recovery" refers to a process in which a liquid culture comprising a protein of interest and one or more undesirable components is subjected to processes to separate the protein of interest from at least some of the undesirable components, such as cells and cell debris.
[0042] As used herein, "cross-flow membrane filtration" refers to a separation technique for liquids that comprises contacting a culture solution containing several soluble or insoluble components with a filtration membrane in an apparatus in a manner that allows the culture solution to flow parallel to the membrane surface and allows at least some of the liquid to penetrate the filtration membrane, thereby separating components in the culture solution into retentate and filtrate. This can also be referred to, in various embodiments, as "membrane separation," "membrane filtration,"
"tangential flow membrane filtration," "tangential flow filtration," "cross-flow filtration," "microfiltration," or "ultrafiltration."
[0043] As used herein, a "filtration membrane," sometimes referred to simply as, a "membrane," is a material that is permeable to liquids and, semipermeable for components dispersed in that liquid, depending on their size, charge, hydrophobicity, or other biophysical properties. The size of particles that can pass through a filtration membrane is determined by its pore size.
[0044] As used herein, the terms "filtrate" and "permeate" refer to the material that passes through a membrane. They are used interchangeably.
[0045] As used herein, the term "retentate" refers to the material retained by a membrane.
[0046] As used herein, "microfiltration" refers to the filtration of liquid through a membrane having a pore size of about 0.02 μm to about 10 μm.
[0047] As used herein, "ultrafiltration" refers to the filtration of liquid through a membrane having a pore size of about 0.001 μm to about 0.02 μm.
[0048] As used herein, "diafiltration" refers to a membrane based filtration that is used to reduce or remove those components in the retentate that can permeate through the membrane by adding more liquid to the retentate and filtering that additional volume of liquid through the membrane. Diafiltration is sometimes referred to as "buffer exchange".
[0049] As used herein, "passage" refers to the movement of a fraction of a component from the retentate through the filtration membrane into the permeate.
[0050] As used herein, "retention" refers to the inability of a component to pass from the retentate through the filtration membrane into the permeate.
[0051] As used herein, "uniform transmembrane pressure" refers to a cross-flow filtration mode of operation where the pressure difference between the retentate side and the permeate side at the retentate inlet of the cross-flow filter is the same as the pressure difference between the retentate side and the permeate side at the retentate outlet of the cross-flow filter. Uniform transmembrane pressure can achieved, for example, by applying pressure to the permeate at the inlet of the cross-flow filter and restricting the permeate flow at the permeate outlet of the cross-flow filter.
[0052] As used herein, the phrase "pressure drop along the membrane element" refers to the pressure difference between the retentate inlet side of a cross-flow membrane filter element and the retentate outlet side of that membrane filter element. In some
embodiments, several cross-flow membrane elements are arranged in series in one membrane housing such that the retentate liquid from one element enters the inlet side of the next element in the series. In the case of having multiple elements in one housing, the pressure drop across the entire series of membrane elements equals the "pressure drop along the membrane element" times the number of elements in the housing.
[0053] As used herein, a "protein product" refers to a protein preparation suitable for providing to an end user, such as a customer. Protein products may include buffers, salts, preservative, reducing agents, sugars, polyols, surfactants, and the like to prolong the shelf-life of the protein of interest.
[0054] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. All reference cited herein are
incorporated by reference. C. Cross-flow Membrane Filtration Recovery Method
[0055] The present methods relate to the recovery of proteins using cross-flow membrane filtration, and to proteins produced by such methods. In some cases, the method allows the purification and recovery of such proteins directly from fermentation broth using only a single membrane cross-flow membrane filtration apparatus.
[0056] A feature of the present methods is the use of two sets of liquid conditions that differentially affect the retention behavior of the protein of interest. Under the first set of conditions, the protein of interest has an apparent molecular weight that is greater than their actual molecular weight, causing them to be retained by the cross-flow membrane filtration membrane. Examples of protein forms in which the apparent molecular weight that is greater than their actual molecular weight include, but are not limited to, multimers, aggregates, or other supramolecular structures, crystals, precipitates, gels, or combinations, thereof. Under the second set of conditions, the proteins of interest have an apparent molecular weight that allows them to pass through the cross-flow membrane filtration membrane. In this case, the apparent molecular weight may be the actual molecular weight.
[0057] Conditions for causing the apparent molecular weight of a particular protein of interest to exceed its actual molecular weight can be determined using conventional methods for sizing macromolecules, including size exclusion chromatography, analytical ultracentrifugation, cross-flow membrane filtration. Exemplary solution
conditions that can be manipulated to cause the apparent molecular weight of a protein of interest to exceed its actual molecular weight are the salt concentration, surfactant concentration, polymer concentration, reducing agent concentration, precipitant concentration, pH, or temperature. Such conditions may induce the formation of multimers, aggregates or supramolecular structures, crystals, precipitates, gels, complexes, conjugates, and the like. Generally, the particular form of the protein of interest that allows it to be retained by a cross-flow membrane filtration membrane is not critical, except to the extent that the protein of interest in that form, preferably with the native structure and function, must be retained by the membrane.
[0058] Under the first set of solution conditions, membrane filtration is performed to retain, concentrate, or enrich the protein of interest, which cannot pass through the membrane. So long as the conditions maintain the protein of interest in a form where the apparent molecular weight of the protein prevents passage through the membrane, the protein solution can be modified as in the case of desalting, buffer exchange, removing unwanted components, addition of formulation components, and the like.
[0059] Retention of the protein of interest can also be increased by the manner in which the cross-flow membrane filtration membrane process is operated. Proteins are retained by cross-flow membrane filtration membranes under conditions of high transmembrane pressure, low cross-flow and/or high retentate solids content. This mode of retention may be combined with the increased retention due to the change in apparent molecular weight of the protein of interest discussed in the previous sections.
[0060] Following the retention of the protein of interest, the method then involves altering the conditions of the culture solution to reduce the apparent molecular weight of the protein of interest. In some cases, the conditions cause the protein of interest to behave according to the true molecular weight. The method then involves recovering the protein of interest as filtrate (i.e., permeate or flow-through) from the membrane. In this manner, cells, cell debris, and other insoluble material are retained by the membrane. Other soluble components that have apparent size larger than the cross- flow membrane filtration membrane pore size are retained. The protein of interest previously retained by the membrane now passes through the cross-flow membrane filtration membrane.
[0061] The passage of the protein of interest into the permeate in the second step of the method can also be accomplished, for example, by changing the operating conditions of the microfilter to those that facilitate the passage of protein of interest,
e.g., low transmembrane pressure, high cross-flow and/or low retentate solids content. Other means of facilitating the passage of the protein of interest known in the art, such as vibration, sonication, backpulsing, or air bubbles, can also be used. Such physical methods for controlling the passage of the protein of interest through the membrane may be combined with each other, as well as with the aforementioned modification of solution conditions to control the apparent molecular weight of the protein of interest.
[0062] The method allows a single cross-flow membrane filtration membrane to be used to separate the protein of interest from cells and cell debris, concentrate the protein of interest, and recover the protein of interest in a preselected solution. Proteins of interest recovered by this method may be sufficiently free of other polypeptides and cellular materials and in a sufficient amount and concentration for formulation into a protein product. However, they can be subjected to further purification and/or concentration if desired. The methods have particular application in an industrial setting where over-expressed proteins can be recovered from broth in very few steps, in some cases in sufficient purity and concentration to use directly as a product.
C. Exemplary Proteins for Recovery
[0063] The methods can be applied to any enzyme or other protein capable of being induced to have an apparent molecular weight greater than its actual molecular weight by manipulation the solution conditions. Exemplary proteins are enzymes, as exemplified by Bacillus licheniformis α-amylase. However, the method can be applied to other enzymes and structural protein.
[0064] Another group of exemplary proteins are the hydrophobins, a class of cysteine- rich polypeptides expressed by filamentous fungi. Hydrophobins are small (~100 amino acids) polypeptides known for their ability to form a hydrophobic coating on the surface of objects, including cells and man-made materials. First discovered in Schizophyllum commune in 1991 , hydrophobins have now been recognized in a number of filamentous fungi. Based on differences in hydropathy and other biophysical properties,
hydrophobins are categorized as being class I or class II.
[0065] The expression of hydrophobin conventionally requires the addition of a large amount of one or more antifoaming agents (i.e., antifoam) during fermentation.
Otherwise, the foam produced by hydrophobin polypeptides saturates breather filters, contaminates vents, causes pressure build-up, and reduces protein yield. As a result, crude concentrates of hydrophobin conventionally contain residual amounts of
antifoam, as well as host cell contaminants, which are undesirable in a hydrophobin preparation, particularly when the hydrophobin is intended as a food additive.
[0066] Hydrophobin can reversibly exist in forms having an apparent molecular weight that is greater than its actual molecular weight, which make hydrophobin well suited for recovery using the present methods. Liquid media containing hydrophobin may be combined with the foam or handled separately. Liquid or foam containing hydrophobin can be continuously or periodically harvested from a fermentor for protein recovery as described, or harvested in batch at the end of a fermentation operation. Liquid media containing hydrophobin may be combined with the foam or handled separately.
[0067] The hydrophobin can be any class I or class Il hydrophobin known in the art, for example, hydrophobin from an Agahcus spp. (e.g., Agahcus bisporus), an Agrocybe spp. (e.g., Agrocybe aegerita), an Ajellomyces spp., (e.g., Ajellomyces capsulatus, Ajellomyces dermatitidis), an Aspergillus spp. (e.g., Aspergillus arvii, Aspergillus brevipes, Aspergillus clavatus, Aspergillus duricaulis, Aspergillus ellipticus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus fumisynnematus, Aspergillus lentulus, Aspergillus niger, Aspergillus unilateralis, Aspergillus viridinutans), a Beauveha spp. (e.g., Beauveha bassiana), a Claviceps spp. (e.g., Claviceps fusiformis), a Coccidioides spp., (e.g., Coccidioides posadasii), a Cochliobolus spp. (e.g., Cochliobolus
heterostrophus), a Crinipellis spp. {e.g., Crinipellis perniciosa), a Cryphonectria spp. (e.g., Cryphonectria parasitica), a Davidiella spp. (e.g., Davidiella tassiana), a
Dictyonema spp. (e.g., Dictyonema glabratum), an Emericella spp. (e.g., Emericella nidulans), a Flammulina spp. (e.g., Flammulina velutipes), a Fusarium spp. {e.g., Fusahum culmorum), a Gibberella spp. (e.g., Gibberella moniliformis), a Glomerella spp. (e.g., Glomerella graminicola), a Grifola spp. (e.g., Grifola frondosa), a
Heterobasidion spp. (e.g., Heterobasidion annosum), a Hypocrea spp. (e.g., Hypocrea jecorina, Hypocrea lixii, Hypocrea virens), a Laccaria spp. (e.g., Laccaha bicolor), a Lentinula spp. (e.g., Lentinula edodes), a Magnaporthe spp. (e.g., Magnaporthe oryzae), a Marasmius spp. (e.g., Marasmius cladophyllus), a Moniliophthora spp. (e.g., Moniliophthora perniciosa), a Neosartorya spp. (e.g., Neosartorya aureola, Neosartorya fennelliae, Neosartorya fischeri, Neosartorya glabra, Neosartorya hiratsukae,
Neosartorya nishimurae, Neosartorya otanii, Neosartorya pseudofischeri, Neosartorya quadricincta, Neosartorya spathulata, Neosartorya spinosa, Neosartorya stramenia, Neosartorya udagawae), a Neurospora spp. (e.g., Neurospora crassa, Neurospora discreta, Neurospora intermedia, Neurospora sitophila, Neurospora tetrasperma), a a
Ophiostoma spp. (e.g., Ophiostoma novo-ulmi, Ophiostoma quercus), a Paracoccidioides spp. (e.g., Paracoccidioides brasiliensis), a Passalora spp. (e.g., Passalora fulva), Paxillus filamentosusPaxillus involutus), a Penicillium spp. (e.g., Penici Ilium camemberti, Penicillium chrysogenum, Penicillium marneffei), a Phlebiopsis spp. (e.g., Phlebiopsis gigantea), a Pisolithus {e.g., Pisolithus tinctorius), a Pleurotus spp., (e.g., Pleurotus ostreatus), a Podospora spp. (e.g., Podospora anserina), a Posfra spp. (e.g., Postia placenta), a Pyrenophora spp. (e.g., Pyrenophora tritici-repentis), a Schizophyllum spp. (e.g., Schizophyllum commune), a Talaromyces spp. (e.g.,
Talaromyces stipitatus), a Trichoderma spp. (e.g., Trichoderma asperellum,
Trichoderma atroviride, Trichoderma viride, Trichoderma reesii [formerly Hypocrea jecorina]), a Tricholoma spp. (e.g., Tricholoma terreum), a Uncinocarpus spp. (e.g., Uncinocarpus reesii), a Verticillium spp. (e.g., Verticillium dahliae), a Xanthodactylon spp. (e.g., Xanthodactylon flammeum), a Xanthoria spp. (e.g., Xanthoria calcicola, Xanthoria capensis, Xanthoria ectaneoides, Xanthoria flammea, Xanthoria karrooensis, Xanthoria ligulata, Xanthoria parietina, Xanthoria turbinata), and the like. Hydrophobins are reviewed in, e.g., Sunde, M ef a/. (2008) Micron 39:773-84; Linder, M. ef a/. (2005) FEMS Microbiol Rev. 29:877-96; and Wosten, H. ef a/. (2001 ) Ann. Rev. Microbiol. 55:625-46. D. Exemplary Culture Solutions
[0068] Culture solutions broadly include solutions comprising the protein of interest and other soluble or insoluble components from which the protein of interest is intended to be separated and recovered. Culture solutions include e.g., fermentation broth, cell suspensions, conditioned media, aqueous lysates, pre-filtered cell-free suspensions, cleared solutions, clarified solutions, concentrated culture solutions, concentrates, and the like.
[0069] The culture solution may include intact or lysed cells, including bacterial, fungal, plant, animal, or insect cells. The culture solution may also include other proteins, non- proteinaceous impurities such as cells or cell debris, nucleic acids, polysaccharides, lipids, chemicals such as antifoam, flocculants, salts, sugars, vitamins, growth factors, precipitants, and the like.
E. Exemplary Cross-flow Membrane Filtration Membranes
[0070] The cross-flow filtration membrane suitable for the present method should have pore size or molecular weight cut-off that is greater than the actual size of the protein of interest. Exemplary pore size of the cross-flow filtration membrane is from about 0.02 μm to about 10 μm, e.g., about 0.02 μm, 0.03 μm, 0.04 μm, 0.05 μm, 0.06 μm, 0.07 μm, 0.08 μm, 0.09 μm, 0.1 μm, 0.2 μm, 0.22 μm, 0.3 μm, 0.4 μm, 0.45 μm, 0.5 μm, 0.6 μm, 0.7 μm, 0.8 μm, 0.9 μm, 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, and the like. Exemplary molecular weight cutoff is from about 1 kD to about 500 kD, e.g., about 1 kD, 5 kD, 10 kD, 20 kD, 50 kD, 100 kD, 200 kD, 500 kD.
[0071] Exemplary membrane materials include polysulfone (PS), polyethersulfone (PES), polyvinylidenefluoride (PVDF), cellulose esters, ceramics, and the like.
[0072] Exemplary types of cross-flow filtration membrane elements are spiral wound modules, tubular membranes, hollow fiber membranes, flatsheet membranes, and the like
[0073] These and other aspects and embodiments of the methods will be apparent from reading the foregoing description and following Examples.
EXAMPLES
[0074] The following examples are provided to illustrate the methods but should not be construed as limiting in scope.
Example 1 : Protein recovery from fermentation broth
[0075] This Example illustrates a process for recovering a protein from fermentation broth using membrane filtration. 160 kg fermentation broth was prepared by culturing Trichoderma reseei that expressed recombinant hydrophobin using conventional techniques.
[0076] The harvest broth was treated by addition of 40 kg of 10% sodium sulfate and the pH was adjusted to 3.9 with sulfuric acid. The mixture was warmed to 50 5C and held for two hours. This operation produced 200 kg treated harvest broth.
[0077] The treated harvest broth was fed to the retentate tank of a cross-flow microfiltration apparatus fitted with a 3.8" x 38" spiral wound KOCH MFK-618, 0.2 μm PES membrane. The retentate mass was first reduced to 120 kg by permeating 80 kg of filtrate, and then diafiltered at constant retentate volume with 270 kg of 2.5 % (w/w)
sodium sulfate solution at 50 °C, 0.3 bar uniform trans-membrane pressure, and at 1 bar pressure drop along the membrane element. Based on SDS-PAGE analysis, the vast majority of hydrophobin was retained with the cells.
[0078] The membrane permeate was directed back to the retentate tank while the diafiltered broth pH of the recirculating broth was raised to 6.2 by addition of 10% (w/w) sodium hydroxide solution to the retentate tank and the system was operated for 1 .4 hours in this mode.
[0079] The broth at pH 6.2 was diafiltered with 320 kg of water, and then concentrated to 80 kg. The permeate product was collected and estimated to contain 91 % of the hydrophobin supplied in the initial fermentation broth. The average permeate flux for the entire process was about 25 kilograms per m2 per hour. The SDS-PAGE gel in Figure 1 shows the protein profile of the initial broth (lane 1 ), the permeate product (lane 2), and the permeate waste (lane 3). Hydrophobin is predominantly found in the in the permeate product.
Example 2: Conventional microfiltration recovery of protein from fermentation broth (comparative example)
[0080] 300 kg fermentation broth was prepared using the same method as described in Example 1. The broth was diluted to 1 ,200 kg with water, and the diluted broth was concentrated to 100 kg by microfiltration under the same conditions as in Example 1. As shown in Figure 2 the hydrophobin and most of the protein impurities were permeated into the filtrate during the concentration step (lane 3). This is in contrast to the method described in Example 1 , where the hydrophobin was selectively retained in the first part of the process and only the impurities permeated into the filtrate.
Example 3: Protein recovery from fermentation broth
[0081] 120 kg fermentation broth was prepared by culturing Trichoderma reseei that expresses recombinant hydrophobin using conventional techniques. The pH was adjusted to 4.0 with sulfuric acid. The mixture was warmed to 50QC and held for two hours.
[0082] Treated broth was diafiltered with 740 kg of 0.5 % (w/w) sodium sulfate solution on a microfilter fitted with four 3.8" x 38" spiral wound (KOCH MFK-618, 0.2 μm PES) membranes in series at 50 °C, 0.3 bar uniform trans-membrane pressure, and at 0.75
bar pressure drop along each membrane element. Hydrophobin was retained with the cells. The average permeate flux was 30 kilograms per m2 per hour.
[0083] The permeate was directed back to the retentate tank while the diafiltered broth was recirculated at 0.05 bar uniform trans-membrane pressure. Then the pH was raised to 5.4 by addition of 10% (w/w) sodium hydroxide solution and the system was operated for 1 .0 hours in this mode.
[0084] The broth at pH 5.4 was then diafiltered with 740 kg of water. The permeate was collected and estimated to contained 98% of the hydrophobin present in the initial fermentation broth. The average permeate flux for the whole process was 30 kilograms per m2 per hour. The process yield was 94%.
[0085] The graph in Figure 3 tracks hydrophobin during the microfiltration process. The word "switch" indicates the point in the process where diafiltration medium was changed from sodium sulfate to water and the broth pH was raised to 5.4.
[0086] Figure 4 shown a series of RP-HPLC traces showing hydrophobin in the initial broth (A), sodium sulfate permeate (B), and water permeate (C). Significant purification of hydrophobin was achieved in the process.
Example 4: Enzyme retention by manipulating the fluid conditions in a tangential flow microfilter
[0087] Bacillus licheniformis that expressed recombinant α-amylase enzyme, as described in PCT Application No. WO08/1 12459, was fermented using conventional techniques. Following fermentation, the broth was lysed using 0.01 % (w/w) lysozyme for 2 hrs, followed by heat treatment at 60 °C for 2hr.
[0088] The lysed broth was cooled and stored at 10°C until use. Cold lysed broth was diluted with 1 part of process water, heated to 50 °C in a jacketed tank, and then held for 2 hours with mixing while maintaining pH 6.5±0.2 using 5% NaOH.
[0089] The diluted cell lysate was fed into the retentate tank of a microfiltration skid with a 3.8" spiral wound KOCH MFK-618, 0.2 μm PES microfiltration element, operated at 50 °C, 0.8 bar uniform trans-membrane pressure, and 1 .3 bar pressure drop along the membrane element. The cell lysate was first concentrated in the microfiltration unit about 3-fold. Then a feed of diluted cell lysate was started to the retentate while at the same time concentrated retentate was removed such that a constant packed solids content of retentate was maintained. As shown in Figure 5, the enzyme passage continuously declined during the process. A control experiment was run at 0.5 bar
uniform transmembrane pressure with the other conditions the same as described above.
Example 5: Protein recovery from cell free protein concentrate
[0090] This Example illustrates a process for recovering a protein from clarified culture solution using microfiltration.
[0091] Clarified culture solution was prepared from fermentation broth described in Example 1 by separating the cells by dead end filtration and dewatering using ultrafiltration. 12 kg of 20% sodium sulfate solution was mixed with 83 kg of this culture solution concentrate, the pH was adjusted to 4.0 with sulfuric acid and the mixture was heated to 50QC in a jacketed process tank.
[0092] The mixture was diafiltered with 240 kg of 2.5% sodium sulfate solution by microfiltration in the same system and under the same operating conditions as were used in Example 1 . The average flux was 25 KMH. As is shown in Figure 6, the hydrophobin protein was largely retained by the microfiltration membrane, whereas all the protein impurities were removed into the permeate.
Example 6: Enzyme recovery and formulation from fermentation broth
[0093] This Example illustrates a process that produces formulated, purified enzyme from a fermentation broth on a single microfiltration unit operation.
[0094] 2.2 kg of fermentation lysate was adjusted to pH 5 using 20% acetic acid. The adjusted lysate was incubated at 50 °C with 80 rpm shaking for 44 hours. 2 kg of the prepared broth were placed into a Sepa Cell benchtop tangential flow filtration module fitted with a flat sheet Microdyn 0.05 μ PES microfiltration membrane, catalog number PM MP005. The system was operated at 5 liters/min cross-flow, 0.7 bar inlet pressure and 50QC with retentate recirculation. The fermentation lysate was diafiltered with 3.7 kg of 50 mM sodium acetate buffer. 95% of the amylase was retained in the retentate after this step.
[0095] The diafiltered lysate was mixed with 8.7 parts (w/w) of Dl water and 5.3 parts (w/w) of 70% (w/w) sorbitol and 0.0012 parts (w/w) calcium chloride adjusted to pH 6.5 with sodium hydroxide solution. The mixture was incubated for 12 hours at 50QC.
[0096] The lysate/sorbitol/calcium chloride mixture was then concentrated on the same Sepa Cell unit under the same operating conditions, except for the inlet pressure,
which was maintained at 0.4 bar. The clear sorbitol/calcium chloride permeate was collected and contained 70% of the amylase enzyme.
[0097] The graph in Figure 7 shows that the activity of enzyme is retained throughout the microfiltration process. The graph in Figure 8 shows the activity-to-dry solids ratio during the first microfiltration process. Enzyme purity increases as inactive dry solids are removed with the diafiltration buffer. The image in Figure 9 shows the physical appearance of the lysate (tube 1 ), treated lysate (tube 2), sodium acetate buffer permeate (tube 3), diafiltered lysate in sorbitol/water/calcium chloride (tube 4), and sorbitol/calcium chloride permeate (tube 5).
Example 7: Enzyme recovery and formulation from cell free enzyme concentrate
[0098] This Example illustrates a process similar to that described in Example 6, but for recovering an enzyme from a clarified culture solution. 2 kg of cell free enzyme concentrate was adjusted to pH 5 with acetic acid and incubated with mixing at 50QC for 44 hours. The prepared concentrate was diafiltered with 50 mM sodium acetate pH 5 on the same apparatus and under the same operating conditions as for the cell- containing lysate in Example 6.
[0099] The diafiltered enzyme concentrate was blended in the microfiltration retentate reservoir with 0.25 parts water, 0.0012 parts calcium chloride and 0.35 parts 70% sorbitol and the pH was raised to 6.5 with sodium hydroxide solution.
[00100] The enzyme/sorbitol/calcium chloride mixture was microfiltered under the same conditions as the enzyme concentrate, except that the inlet pressure was lowered to 0.5 bar.
[00101] The graph in Figure 10 shows the activity-to-dry solids ratio during the first microfiltration process. The enzyme purity increased as inactive dry solids were removed with the diafiltration buffer. The Table in Figure 1 1 shows enzyme passage during the course of the microfiltration process. Passage refers to the ratio of permeate activity and retentate activity. As the permeate volume increased, enzyme passage slowed.
Claims
1. A method for recovering a protein of interest from a culture solution using cross-flow membrane filtration, comprising:
subjecting a culture solution comprising a protein of interest to cross-flow membrane filtration using a first membrane under a first set of conditions that cause the protein of interest to be retained as retentate to allow purification, concentration, and/or buffer exchange of the protein of interest;
wherein under a second set of conditions, the first membrane allows the passage of the protein of interest.
2. The method of claim 1 , further comprising:
exposing the protein of interest retained by the first cross-flow membrane to a second cross-flow membrane, under a second set of conditions that cause the protein of interest pass through the second membrane as filtrate to allow purification and/or recovery of the protein of interest.
3. The method of claim 1 , wherein the first membrane has a pore size of from about 0.02 μm to about 10 μm.
4. The method of claim 2, wherein the first membrane and the second membrane independently have a pore size of from about 0.02 μm to about 10 μm.
5. The method of claim 2 or 4, wherein the first membrane and the second membrane have substantially the same pore size.
6. The method of claim 2, 4, or 5, wherein the first membrane and the second membrane are the same membrane.
7. The method of claim 1 wherein the first membrane is a series of membranes.
8. The method of any of claims 2 and 4-6, wherein the first and/or second membrane is a series of membranes.
9. The method of any of the preceding claims, wherein the culture solution comprising the protein of interest further comprises intact cells or cell debris, and wherein the intact cells or cell debris are retained on the first membrane, along with the protein of interest, under the first set of conditions.
10. The method of any of claims 2, 4-6, or 8-9, wherein the culture solution comprising the protein of interest further comprises intact cells or cell debris, and wherein the intact cells or cell debris are retained with the protein of interest under the first set of conditions and separated from the protein of interest under the second set of conditions.
1 1 . The method of claims 9 or 10, wherein the intact cells or cell debris are from filamentous fungi or bacteria.
12. The method of any of the preceding claims, wherein the culture solution comprising the protein of interest further comprises additional molecules that are not retained by the first membrane.
13. The method of any of the preceding claims, wherein the first set of conditions cause the protein of interest to exhibit an apparent molecular weight greater than its true molecular weight.
14. The method of any of the preceding claims, wherein the first set of conditions cause the protein of interest to form multimers, to aggregate, to crystallize, to precipitate, to form a gel, or combinations, thereof.
15. The method of any of the preceding claims, wherein the first set of conditions differs from the second set of conditions in transmembrane pressure, cross- flow, and/or solids concentration.
16. The method of any of the preceding claims, wherein the first set of conditions uses a transmembrane pressure that causes retention of the protein of interest on the first membrane and where the second set of conditions uses a transmembrane pressure that allows permeation of the protein of interest through the second membrane.
17. The method of any of the preceding claims, wherein the second set of conditions cause the protein of interest to exhibit its true molecular weight.
18. The method of any of the preceding claims, wherein the second set of conditions are in the form of an aqueous solution suitable for formulating the protein of interest into an end product.
19. The method of any of the preceding claims, wherein the first set of conditions differs from the second set of conditions in salt concentration, surfactant concentration, polymer concentration, chaotrope concentration, reducing agent concentration, anti-foam concentration, precipitant concentration, pH, or temperature.
20. The method of any of the preceding claims, wherein the protein of interest is an enzyme.
21 . The method of any of the preceding claims, wherein the protein of interest is hydrophobin.
22. A protein of interest produced by the method of any of the preceding claims.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK10742695.9T DK2464446T3 (en) | 2009-08-10 | 2010-08-10 | CROSS-FLOW MEMBRANE FILTRATION BASED PROTEIN RECOVERY PROCEDURE |
US13/389,251 US8993294B2 (en) | 2009-08-10 | 2010-08-10 | Cross-flow membrane filtration-based process for protein recovery |
CN201080045459.3A CN102574059B (en) | 2009-08-10 | 2010-08-10 | Cross-flow membrane filtration-based process for protein recovery |
EP10742695.9A EP2464446B1 (en) | 2009-08-10 | 2010-08-10 | Cross-flow membrane filtration-based process for protein recovery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23272809P | 2009-08-10 | 2009-08-10 | |
US61/232,728 | 2009-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011019686A1 true WO2011019686A1 (en) | 2011-02-17 |
Family
ID=43244704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/044964 WO2011019686A1 (en) | 2009-08-10 | 2010-08-10 | Cross-flow membrane filtration-based process for protein recovery |
Country Status (6)
Country | Link |
---|---|
US (1) | US8993294B2 (en) |
EP (1) | EP2464446B1 (en) |
CN (1) | CN102574059B (en) |
AR (1) | AR077838A1 (en) |
DK (1) | DK2464446T3 (en) |
WO (1) | WO2011019686A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012135433A1 (en) | 2011-03-29 | 2012-10-04 | Danisco Us Inc. | Methods of foam control |
WO2013151799A1 (en) * | 2012-03-29 | 2013-10-10 | Lockheed Martin Corporation | Tunable layered graphene membrane configuration for filtration and selective isolation and recovery devices |
WO2013177153A1 (en) | 2012-05-21 | 2013-11-28 | Danisco Us Inc. | Trichoderma hydrophobin production |
WO2015051121A1 (en) | 2013-10-02 | 2015-04-09 | E. I. Du Pont De Nemours And Company | Hydrophobin composition and process for treating surfaces |
US9028663B2 (en) | 2012-03-21 | 2015-05-12 | Lockheed Martin Corporation | Molecular separation device |
EP2784156A4 (en) * | 2011-11-21 | 2015-07-15 | Toray Industries | Method for producing cellulase, and apparatus for said method |
US9463421B2 (en) | 2012-03-29 | 2016-10-11 | Lockheed Martin Corporation | Planar filtration and selective isolation and recovery device |
WO2016167871A1 (en) * | 2015-04-17 | 2016-10-20 | Emd Millipore Corporation | Method of purifying a biological materia of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
US9610546B2 (en) | 2014-03-12 | 2017-04-04 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene and methods for use thereof |
US9623352B2 (en) | 2010-08-10 | 2017-04-18 | Emd Millipore Corporation | Method for retrovirus removal |
US9744617B2 (en) | 2014-01-31 | 2017-08-29 | Lockheed Martin Corporation | Methods for perforating multi-layer graphene through ion bombardment |
US9750829B2 (en) | 2009-03-19 | 2017-09-05 | Emd Millipore Corporation | Removal of microorganisms from fluid samples using nanofiber filtration media |
US9828591B2 (en) | 2010-10-20 | 2017-11-28 | Danisco Us Inc | Thermostable trichoderma cellulase |
US9833748B2 (en) | 2010-08-25 | 2017-12-05 | Lockheed Martin Corporation | Perforated graphene deionization or desalination |
US9834809B2 (en) | 2014-02-28 | 2017-12-05 | Lockheed Martin Corporation | Syringe for obtaining nano-sized materials for selective assays and related methods of use |
US9844757B2 (en) | 2014-03-12 | 2017-12-19 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene and methods for use thereof |
US9870895B2 (en) | 2014-01-31 | 2018-01-16 | Lockheed Martin Corporation | Methods for perforating two-dimensional materials using a broad ion field |
US10005038B2 (en) | 2014-09-02 | 2018-06-26 | Lockheed Martin Corporation | Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same |
US10017852B2 (en) | 2016-04-14 | 2018-07-10 | Lockheed Martin Corporation | Method for treating graphene sheets for large-scale transfer using free-float method |
US10118130B2 (en) | 2016-04-14 | 2018-11-06 | Lockheed Martin Corporation | Two-dimensional membrane structures having flow passages |
AU2016256734B2 (en) * | 2011-03-29 | 2018-11-08 | Danisco Us Inc. | Methods of foam control |
US10203295B2 (en) | 2016-04-14 | 2019-02-12 | Lockheed Martin Corporation | Methods for in situ monitoring and control of defect formation or healing |
US10201784B2 (en) | 2013-03-12 | 2019-02-12 | Lockheed Martin Corporation | Method for forming perforated graphene with uniform aperture size |
US10213746B2 (en) | 2016-04-14 | 2019-02-26 | Lockheed Martin Corporation | Selective interfacial mitigation of graphene defects |
US10376845B2 (en) | 2016-04-14 | 2019-08-13 | Lockheed Martin Corporation | Membranes with tunable selectivity |
US10418143B2 (en) | 2015-08-05 | 2019-09-17 | Lockheed Martin Corporation | Perforatable sheets of graphene-based material |
US10471199B2 (en) | 2013-06-21 | 2019-11-12 | Lockheed Martin Corporation | Graphene-based filter for isolating a substance from blood |
US10500546B2 (en) | 2014-01-31 | 2019-12-10 | Lockheed Martin Corporation | Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer |
US10653824B2 (en) | 2012-05-25 | 2020-05-19 | Lockheed Martin Corporation | Two-dimensional materials and uses thereof |
US10696554B2 (en) | 2015-08-06 | 2020-06-30 | Lockheed Martin Corporation | Nanoparticle modification and perforation of graphene |
US10980919B2 (en) | 2016-04-14 | 2021-04-20 | Lockheed Martin Corporation | Methods for in vivo and in vitro use of graphene and other two-dimensional materials |
EP3822357A1 (en) * | 2019-11-18 | 2021-05-19 | IFP Energies nouvelles | Method of producing enzymes by a strain belonging to a filamentous fungus |
US11154821B2 (en) | 2011-04-01 | 2021-10-26 | Emd Millipore Corporation | Nanofiber containing composite membrane structures |
US12059644B2 (en) | 2014-06-26 | 2024-08-13 | Emd Millipore Corporation | Filter structure with enhanced dirt holding capacity |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3370543A4 (en) * | 2015-11-03 | 2019-07-31 | Aspire Food Group USA, Inc. | Insect products and methods of manufacture thereof |
US20200109388A1 (en) | 2017-04-03 | 2020-04-09 | Novozymes A/S | Recovery Process |
CN113993878A (en) | 2019-06-13 | 2022-01-28 | 巴斯夫欧洲公司 | Method for recovering protein from fermentation liquor by using divalent cation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57206378A (en) * | 1981-06-12 | 1982-12-17 | Kuraray Co Ltd | Filtering method of sake |
EP0193046A2 (en) * | 1985-02-26 | 1986-09-03 | HAARMANN & REIMER CORP. | Process to recover crystalline enzymes |
EP0363896A2 (en) * | 1988-10-12 | 1990-04-18 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
US5262053A (en) * | 1988-07-15 | 1993-11-16 | Filtrox-Werk Ag | Filtration process, use of stabilizers installation for a filtration process, and procedure for operating said installation |
WO2001010470A1 (en) * | 1999-08-06 | 2001-02-15 | Baxter Aktiengesellschaft | Devices and methods for removing pathogens from biological fluids |
US20020020668A1 (en) * | 2000-05-18 | 2002-02-21 | Novozymes A/S | Microfiltration using activated carbon |
WO2008112459A2 (en) | 2007-03-09 | 2008-09-18 | Danisco Us Inc., Genencor Division | Alkaliphilic bacillus species a-amylase variants, compositions comprising a-amylase variants, and methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL147861A (en) * | 1999-07-30 | 2005-08-31 | Genentech Inc | Charged filtration membranes and uses thereof |
GB0002661D0 (en) * | 2000-02-04 | 2000-03-29 | Biomade B V | Method of stabilizing a hydrophobin-containing solution and a method of coating a surface with a hydrophobin |
US8152999B2 (en) * | 2004-05-21 | 2012-04-10 | Wisconsin Alumni Research Foundation | Membrane cascade-based separation |
-
2010
- 2010-08-10 EP EP10742695.9A patent/EP2464446B1/en active Active
- 2010-08-10 AR ARP100102927A patent/AR077838A1/en active IP Right Grant
- 2010-08-10 DK DK10742695.9T patent/DK2464446T3/en active
- 2010-08-10 US US13/389,251 patent/US8993294B2/en active Active
- 2010-08-10 CN CN201080045459.3A patent/CN102574059B/en active Active
- 2010-08-10 WO PCT/US2010/044964 patent/WO2011019686A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57206378A (en) * | 1981-06-12 | 1982-12-17 | Kuraray Co Ltd | Filtering method of sake |
EP0193046A2 (en) * | 1985-02-26 | 1986-09-03 | HAARMANN & REIMER CORP. | Process to recover crystalline enzymes |
US5262053A (en) * | 1988-07-15 | 1993-11-16 | Filtrox-Werk Ag | Filtration process, use of stabilizers installation for a filtration process, and procedure for operating said installation |
EP0363896A2 (en) * | 1988-10-12 | 1990-04-18 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
WO2001010470A1 (en) * | 1999-08-06 | 2001-02-15 | Baxter Aktiengesellschaft | Devices and methods for removing pathogens from biological fluids |
US20020020668A1 (en) * | 2000-05-18 | 2002-02-21 | Novozymes A/S | Microfiltration using activated carbon |
WO2008112459A2 (en) | 2007-03-09 | 2008-09-18 | Danisco Us Inc., Genencor Division | Alkaliphilic bacillus species a-amylase variants, compositions comprising a-amylase variants, and methods of use |
Non-Patent Citations (4)
Title |
---|
LINDER, M. ET AL., FEMS MICROBIOL REV., vol. 29, 2005, pages 877 - 96 |
SUNDE, M ET AL., MICRON, vol. 39, 2008, pages 773 - 84 |
VAN REIS R ET AL: "High-performance tangential flow filtration using charged membranes", JOURNAL OF MEMBRANE SCIENCE, ELSEVIER SCIENTIFIC PUBL.COMPANY. AMSTERDAM, NL, vol. 159, no. 1-2, 1 July 1999 (1999-07-01), pages 133 - 142, XP004169169, ISSN: 0376-7388, DOI: DOI:10.1016/S0376-7388(99)00048-4 * |
WOSTEN, H. ET AL., ANN. REV. MICROBIOL., vol. 55, 2001, pages 625 - 46 |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10064965B2 (en) | 2009-03-19 | 2018-09-04 | Emd Millipore Corporation | Removal of microorganisms from fluid samples using nanofiber filtration media |
US9943616B2 (en) | 2009-03-19 | 2018-04-17 | Emd Millipore Corporation | Removal of microorganisms from fluid samples using nanofiber filtration media |
US9889214B2 (en) | 2009-03-19 | 2018-02-13 | Emd Millipore Corporation | Removal of microorganisms from fluid samples using nanofiber filtration media |
US9750829B2 (en) | 2009-03-19 | 2017-09-05 | Emd Millipore Corporation | Removal of microorganisms from fluid samples using nanofiber filtration media |
US10722602B2 (en) | 2009-03-19 | 2020-07-28 | Emd Millipore Corporation | Removal of microorganisms from fluid samples using nanofiber filtration media |
US9623352B2 (en) | 2010-08-10 | 2017-04-18 | Emd Millipore Corporation | Method for retrovirus removal |
US10252199B2 (en) | 2010-08-10 | 2019-04-09 | Emd Millipore Corporation | Method for retrovirus removal |
US9833748B2 (en) | 2010-08-25 | 2017-12-05 | Lockheed Martin Corporation | Perforated graphene deionization or desalination |
US9828591B2 (en) | 2010-10-20 | 2017-11-28 | Danisco Us Inc | Thermostable trichoderma cellulase |
WO2012135433A1 (en) | 2011-03-29 | 2012-10-04 | Danisco Us Inc. | Methods of foam control |
AU2016256734B2 (en) * | 2011-03-29 | 2018-11-08 | Danisco Us Inc. | Methods of foam control |
EP2691509A1 (en) * | 2011-03-29 | 2014-02-05 | Danisco US Inc. | Methods of foam control |
EP2691509A4 (en) * | 2011-03-29 | 2014-10-08 | Danisco Us Inc | Methods of foam control |
US11154821B2 (en) | 2011-04-01 | 2021-10-26 | Emd Millipore Corporation | Nanofiber containing composite membrane structures |
EP2784156A4 (en) * | 2011-11-21 | 2015-07-15 | Toray Industries | Method for producing cellulase, and apparatus for said method |
US11253818B2 (en) | 2011-11-21 | 2022-02-22 | Toray Industries, Inc. | Method for producing cellulase and apparatus for said method |
US9028663B2 (en) | 2012-03-21 | 2015-05-12 | Lockheed Martin Corporation | Molecular separation device |
US9095823B2 (en) | 2012-03-29 | 2015-08-04 | Lockheed Martin Corporation | Tunable layered membrane configuration for filtration and selective isolation and recovery devices |
WO2013151799A1 (en) * | 2012-03-29 | 2013-10-10 | Lockheed Martin Corporation | Tunable layered graphene membrane configuration for filtration and selective isolation and recovery devices |
US9463421B2 (en) | 2012-03-29 | 2016-10-11 | Lockheed Martin Corporation | Planar filtration and selective isolation and recovery device |
WO2013177153A1 (en) | 2012-05-21 | 2013-11-28 | Danisco Us Inc. | Trichoderma hydrophobin production |
US10653824B2 (en) | 2012-05-25 | 2020-05-19 | Lockheed Martin Corporation | Two-dimensional materials and uses thereof |
US10201784B2 (en) | 2013-03-12 | 2019-02-12 | Lockheed Martin Corporation | Method for forming perforated graphene with uniform aperture size |
US10471199B2 (en) | 2013-06-21 | 2019-11-12 | Lockheed Martin Corporation | Graphene-based filter for isolating a substance from blood |
WO2015051121A1 (en) | 2013-10-02 | 2015-04-09 | E. I. Du Pont De Nemours And Company | Hydrophobin composition and process for treating surfaces |
US10500546B2 (en) | 2014-01-31 | 2019-12-10 | Lockheed Martin Corporation | Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer |
US9870895B2 (en) | 2014-01-31 | 2018-01-16 | Lockheed Martin Corporation | Methods for perforating two-dimensional materials using a broad ion field |
US9744617B2 (en) | 2014-01-31 | 2017-08-29 | Lockheed Martin Corporation | Methods for perforating multi-layer graphene through ion bombardment |
US9834809B2 (en) | 2014-02-28 | 2017-12-05 | Lockheed Martin Corporation | Syringe for obtaining nano-sized materials for selective assays and related methods of use |
US9610546B2 (en) | 2014-03-12 | 2017-04-04 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene and methods for use thereof |
US9844757B2 (en) | 2014-03-12 | 2017-12-19 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene and methods for use thereof |
US12059644B2 (en) | 2014-06-26 | 2024-08-13 | Emd Millipore Corporation | Filter structure with enhanced dirt holding capacity |
US10005038B2 (en) | 2014-09-02 | 2018-06-26 | Lockheed Martin Corporation | Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same |
KR102206963B1 (en) | 2015-04-17 | 2021-01-25 | 이엠디 밀리포어 코포레이션 | Method of purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
KR20190128259A (en) * | 2015-04-17 | 2019-11-15 | 이엠디 밀리포어 코포레이션 | Method of purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
KR102206959B1 (en) | 2015-04-17 | 2021-01-25 | 이엠디 밀리포어 코포레이션 | Method of purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
KR20190060884A (en) * | 2015-04-17 | 2019-06-03 | 이엠디 밀리포어 코포레이션 | Method of purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
US10675588B2 (en) | 2015-04-17 | 2020-06-09 | Emd Millipore Corporation | Method of purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
WO2016167871A1 (en) * | 2015-04-17 | 2016-10-20 | Emd Millipore Corporation | Method of purifying a biological materia of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
US10418143B2 (en) | 2015-08-05 | 2019-09-17 | Lockheed Martin Corporation | Perforatable sheets of graphene-based material |
US10696554B2 (en) | 2015-08-06 | 2020-06-30 | Lockheed Martin Corporation | Nanoparticle modification and perforation of graphene |
US10376845B2 (en) | 2016-04-14 | 2019-08-13 | Lockheed Martin Corporation | Membranes with tunable selectivity |
US10118130B2 (en) | 2016-04-14 | 2018-11-06 | Lockheed Martin Corporation | Two-dimensional membrane structures having flow passages |
US10980919B2 (en) | 2016-04-14 | 2021-04-20 | Lockheed Martin Corporation | Methods for in vivo and in vitro use of graphene and other two-dimensional materials |
US10981120B2 (en) | 2016-04-14 | 2021-04-20 | Lockheed Martin Corporation | Selective interfacial mitigation of graphene defects |
US10213746B2 (en) | 2016-04-14 | 2019-02-26 | Lockheed Martin Corporation | Selective interfacial mitigation of graphene defects |
US10017852B2 (en) | 2016-04-14 | 2018-07-10 | Lockheed Martin Corporation | Method for treating graphene sheets for large-scale transfer using free-float method |
US10203295B2 (en) | 2016-04-14 | 2019-02-12 | Lockheed Martin Corporation | Methods for in situ monitoring and control of defect formation or healing |
EP3822357A1 (en) * | 2019-11-18 | 2021-05-19 | IFP Energies nouvelles | Method of producing enzymes by a strain belonging to a filamentous fungus |
FR3103196A1 (en) * | 2019-11-18 | 2021-05-21 | IFP Energies Nouvelles | PROCESS FOR THE PRODUCTION OF ENZYMES BY A STRAIN BELONGING TO A FILAMENTOUS FUNGI |
US11560581B2 (en) | 2019-11-18 | 2023-01-24 | IFP Energies Nouvelles | Process for producing enzymes with a strain belonging to a filamentous fungus |
Also Published As
Publication number | Publication date |
---|---|
CN102574059A (en) | 2012-07-11 |
DK2464446T3 (en) | 2015-03-30 |
CN102574059B (en) | 2014-12-10 |
EP2464446A1 (en) | 2012-06-20 |
EP2464446B1 (en) | 2014-12-24 |
US8993294B2 (en) | 2015-03-31 |
US20120220009A1 (en) | 2012-08-30 |
AR077838A1 (en) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8993294B2 (en) | Cross-flow membrane filtration-based process for protein recovery | |
EP0832108B1 (en) | Process for recovering water-insoluble compounds from a fermentation broth | |
EP2007506B1 (en) | Tangential flow filtration apparatuses, systems, and processes for the separation of compounds | |
JP6985282B2 (en) | Method for purifying type 7 collagen | |
US10987629B2 (en) | Method for removing biopolymer aggregates and viruses from a fluid | |
Charcosset | Ultrafiltration, microfiltration, nanofiltration and reverse osmosis in integrated membrane processes | |
US6515115B1 (en) | Membrane filtration | |
Rajeeva et al. | Bioprocessing of laccase produced by submerged culture of Ganoderma sp. WR-1 | |
Matson | Membrane bioseparations | |
Schlosser | Membrane filtration | |
Russotti et al. | Development of a pilot‐scale microfiltration harvest for the isolation of physostigmine from Streptomyces griseofuscus broth | |
CN106146608A (en) | A kind of extraction preparation method of apidaecin | |
Chew et al. | Membrane-based separation processes | |
Muthukumarappan et al. | Membrane processing | |
CN206089712U (en) | Whole blood peptide powder extraction element | |
EP3083544B1 (en) | Process for the separation of dicarboxylic acids from aqueous mixtures | |
Ghosh | Bioseparations using integrated membrane processes | |
JPH11215980A (en) | Treatment of liquid containing microbial cell | |
Su et al. | Crossflow membrane filtration | |
Erkal et al. | Monoklonal Antikor Üretimleri İçin Alt Akım Prosesleri | |
Matson | Membrone biosepdrotions | |
Kuriyel et al. | 14 Advancements in Membrane Processes for Pharmaceutical Applications | |
CA2735505C (en) | Method of producing butanol | |
MXPA97009740A (en) | Process to recover insoluble compounds in water from a fermentac broth | |
Bouchoux et al. | Introduction of nanofiltration in a production process of fermented organic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080045459.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10742695 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010742695 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13389251 Country of ref document: US |